Amyotrophic lateral sclerosis strips away the ability to move, speak, and eventually breathe, usually killing within two to five years of diagnosis. For decades, researchers have focused on what goes wrong inside motor neurons. A study published in June 2026 in Cell Reports shifts attention to an unexpected accomplice: a sugar molecule churned out by common gut bacteria that, in mice carrying the most prevalent ALS-linked mutation, ignites a cascade of inflammation reaching the brain and spinal cord. When the research team broke that sugar down with an enzyme delivered to the gut, the mice regained motor function and survived longer.
The results do not prove the same mechanism operates in people. But they offer the clearest evidence yet that, for at least one major genetic form of ALS, the gut microbiome may act as a switch that helps determine whether the disease ever turns on.
The mutation, the microbe, and the sugar
About 40 percent of familial ALS cases and up to 10 percent of cases with no family history trace back to a repeat expansion in a gene called C9orf72. Not everyone who carries the expansion gets sick, a puzzle that has long suggested environmental factors play a role. The new study zeroed in on one such factor: a form of glycogen produced by ordinary commensal bacteria in the gut.
Working with mice engineered to lack functional C9orf72, the team at Case Western Reserve University raised some animals in germ-free isolators, meaning they had no microbiome at all, and then selectively colonized them with specific bacterial strains. Mice that received glycogen-producing bacteria developed severe inflammation. Mice colonized with strains that do not make glycogen did not.
Using single-cell RNA sequencing of brain tissue and metatranscriptomic profiling of gut communities, the researchers traced the damage to myeloid cells, the immune system’s front-line sentinels in blood and tissue. In healthy animals, C9orf72 helps these cells tolerate routine microbial byproducts. Without it, microbial glycogen triggered runaway activation of the STING signaling pathway and a flood of type I interferons, molecules the immune system normally reserves for fighting viral infections. The result was friendly fire aimed at the animal’s own nervous system.
Two immune pathways, one genetic vulnerability
The STING connection was not entirely new. A 2020 study published in Nature by an overlapping group of researchers showed that losing C9orf72 in myeloid cells alone was enough to trigger STING-driven autoinflammation, even when motor neurons were genetically normal. Transcriptomic data from that work, deposited in the NIH Gene Expression Omnibus, confirmed that type I interferon gene signatures spiked in myeloid cells lacking the gene.
The Cell Reports paper adds a critical piece: the identity of the bacterial product that lights the fuse.
A parallel line of research from the same group, published in 2024, showed that C9orf72 also keeps a second immune pathway, IL-17A signaling, in check. IL-17A is a cytokine tied to inflammation at barrier tissues like the gut lining. If microbial glycogen breaches a leaky gut barrier, dysregulated IL-17A could amplify the damage. Together, the two pathways, STING/type I interferon and IL-17A, form converging routes by which a single genetic vulnerability turns bacterial sugar into neurological harm.
Same genes, different cages, different fates
One of the most striking earlier findings came from housing genetically identical C9orf72-deficient mice in separate animal facilities, each with its own resident microbial ecosystem. Mice in one vivarium developed severe autoimmune symptoms. Mice in another stayed relatively healthy. The only variable that differed meaningfully was the composition of the gut microbiome.
That observation, reported in the same 2020 Nature paper, reframed the microbiome as something closer to a volume knob on genetic ALS risk. The new glycogen data now suggest what, specifically, the knob is turning: the abundance of bacteria that produce this particular sugar, and the quantity of glycogen reaching immune cells that can no longer handle it.
What the enzyme experiment showed
The most dramatic result in the Cell Reports study was the enzyme intervention. Researchers administered a glycogen-degrading enzyme to C9orf72-deficient mice that had already been colonized with glycogen-producing bacteria. The animals showed measurable improvements in motor function and lived longer than untreated controls.
That outcome is striking, but it comes with important caveats. The experiments were short-duration. Long-term safety data do not exist. And the enzyme would need to be precise enough to break down microbial glycogen without stripping glycogen stores that the host’s own cells depend on for energy. Translating this into a therapy for people would require clearing substantial pharmacological and regulatory hurdles.
What has not been shown in humans
No study has yet measured microbial glycogen concentrations in stool or blood from human ALS patients and compared them with healthy controls. All of the glycogen-specific findings come from mouse colonization experiments.
Earlier work using a different ALS mouse model, one based on mutations in the SOD1 gene, showed that individual bacterial species can worsen or ease symptoms and reported preliminary microbiome differences between ALS patients and household controls. But that study focused on other metabolites, particularly nicotinamide, not glycogen, and relied on broad bacterial profiling rather than strain-level genomics.
No one has tested whether purified microbial glycogen triggers the same STING or IL-17A cascades in human immune cells taken from C9orf72 expansion carriers. And no clinical trial has explored whether clearing microbial glycogen before symptoms appear could delay or prevent disease in presymptomatic carriers. That idea is testable in principle through blood-based immune profiling, but no such study has been reported.
There is also a question of specificity. The current data cannot distinguish whether microbial glycogen is uniquely toxic in the context of C9orf72 deficiency or whether it is one of several interchangeable microbial triggers that could push a primed immune system past its threshold. Other bacterial products, including lipopolysaccharides and nucleic acids, might converge on the same pathways. Without systematic screening of diverse microbial molecules in C9orf72-deficient models, the field risks overcommitting to a single metabolite.
What this changes about how we think about ALS
Even with those gaps, the conceptual shift is significant. The work reframes at least one major genetic subset of ALS as a disorder in which inherited immune vulnerability collides with an external microbial cue. It suggests that for people carrying C9orf72 expansions, the gut may matter as much as the spinal cord.
The strongest evidence comes from the germ-free colonization experiments, where researchers could introduce specific bacteria and measure the immune response at single-cell resolution. That approach eliminates the noise of a pre-existing microbial community and allows cause-and-effect conclusions that observational human studies cannot yet provide. The vivarium experiments add ecological validity: genetically identical animals develop radically different disease outcomes depending on which microbes surround them.
Human data remain sparse and exploratory. Small ALS patient cohorts have hinted that gut composition and circulating metabolites differ from those of healthy controls, but sample sizes are modest and methods vary across studies. No published dataset links microbial glycogen levels, specific glycogen-producing strains, and immune activation in people with C9orf72 expansions. Any direct extrapolation from the mouse glycogen findings to human ALS risk should, for now, be considered speculative.
What the findings do justify is a sharper look at which bacterial species and metabolites populate the guts of people at genetic risk for ALS. Future studies pairing deep metagenomic sequencing, metabolomics, and immune profiling in expansion carriers, both those who are symptomatic and those who are not, will test whether the bacterial glycogen story in mice has a human counterpart. Until that work is done, the safest reading is that the microbiome represents a modifiable risk layer sitting on top of fixed genetic susceptibility, one that could eventually complement neuron-focused therapies rather than replace them.
For the roughly 30,000 Americans living with ALS at any given time, that possibility, however preliminary, matters. If the gut turns out to be a place where the disease can be intercepted, it would open a front in ALS research that barely existed five years ago.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
